Skip to main content

Substance Use Disorders and HIV

No Ratings

AAHIVM Course Banner
1.0 CEUs
Substance Use Disorders and HIV

Module Description  Designed for the HIV health care professional, this webinar will look at the clinical manifestation of substance use disorders and HIV. Also covered in the webinar: diagnostic criteria; etiology and physiology of substance use disorders; the impact of substance use disorders on health; and evidence-based interventions, including prescribing and monitoring psychotropic medications.

Credit Dates 05/01/2024 – 04/30/2025

Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.

This activity is supported by an independent educational grant from Gilead Sciences.
Learning Objectives
  • Discuss the data about HIV and substance use.
  • Explain how HIV and substance use disorders are intertwined.
  • Discuss the strategies and therapeutic approaches in the management of co-ocurring substance use disorders and HIV.
  • Identify elements of an integrated care approach.

Target Audience
This activity is intended for physicians, PAs, NPs, RNs, and pharmacists who are engaged in the care of people with HIV.

Estimated Time to Complete the Activity: 1 hour

PresentersAntoine Douaihy, MD
Professor of Psychiatry and Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Instructions for Credit
There are no fees for participating and receiving CME/CE credit for this activity.

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from May 1, 2024 through April 30, 2025:

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Visit https://www.paceducation.com/HIVMH4E
  4. Complete the activity evaluation
For Pharmacists: Upon successfully completing the post-test (if applicable) with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

If you have questions regarding the certification of this activity, please contact PACE by visiting ttps://partnersed.com.

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008073-9999-24-096-H02-P)

Type of Activity: Application

Continuing Nursing Education The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

Disclosure of Conflict of Interest
PACE requires every individual who are in a position to control the content to disclose all financial relationships with ineligible companies that have occurred in the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling or distributing health care products use by or on patients.

All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
 
Dr. Douaihy has nothing to disclose.

Planners and Managers
The PACE planners and managers have nothing to disclose.
The Academy planners and managers have nothing to disclose.

Media: Internet

Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.